Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchVergent Bioscience announces FDA Fast Track designation for abenacianine injection to enhance tumor visualization during lung surgery.
Jan 07, 2025
MinneapolisBiotechnologyHealth CareTherapeutics
Product Description
Vergent Bioscience has received FDA Fast Track designation for its investigational tumor-targeted imaging agent, abenacianine for injection (VGT-309), aimed at improving tumor visualization for surgeons in lung cancer surgeries. This designation emphasizes the importance of addressing challenges in minimally invasive surgical procedures.
Company Information
Company
Vergent Bioscience
Location
5810 W 78TH ST
Minneapolis, Minnesota, United States
About
Vergent Bioscience is a clinical-stage biotechnology company that is helping surgeons realize the full potential of minimally invasive and robotic-assisted surgery by significantly improving the visibility of tumors.
Vergent’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all tumor tissue is removed. We are first evaluating VGT-309 in lung cancer, with the potential to expand its application to a wide range of solid tumors.
Our approach directly addresses the clinical need and market opportunity for advanced visualization in open, laparoscopic, and robotic-assisted surgical procedures.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Vergent Bioscience ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
MinneapolisBiotechnologyHealth CareTherapeutics